Brazilian company CBD Vida and Kemin Industries last week announced a partnership to distribute cannabinoid-containing drugs in Brazil.
Kemin is a global supplier of special ingredients for human and animal health and nutrition, valued at more than $1 billion. Through MedPharm, a CBD manufacturer in the state of Iowa, and receiving consultancy from Kemin, CBD Vida promises to bring products with pharmaceutical standards at competitive prices to the Brazilian market.
The South American country has seen recent changes in its regulations for cannabis derivatives, CBD Vida explained. New regulations allow patients to buy CBD-containing products under prescription, directly from pharmacies
“As two global companies, we share the same vision to improve and transform the quality of life for people around the world. Our partnership ensures Brazilian patients have access to quality hemp derivatives that are scientifically created with extreme care,” said Fabio Candello, CEO of CBD Vida.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!